Biotechnology
Compare Stocks
2 / 10Stock Comparison
DYAI vs CDXS
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
DYAI vs CDXS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $28M | $242M |
| Revenue (TTM) | $3M | $70M |
| Net Income (TTM) | $-7M | $-44M |
| Gross Margin | 42.2% | 79.5% |
| Operating Margin | -273.4% | -54.5% |
| Total Debt | $5M | $73M |
| Cash & Equiv. | $7M | $51M |
DYAI vs CDXS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Dyadic Internationa… (DYAI) | 100 | 12.5 | -87.5% |
| Codexis, Inc. (CDXS) | 100 | 21.4 | -78.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DYAI vs CDXS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
DYAI is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.98
- Rev growth 20.6%, EPS growth 16.7%, 3Y rev CAGR 13.3%
- Lower volatility, beta 0.98, current ratio 4.01x
CDXS carries the broadest edge in this set and is the clearest fit for long-term compounding.
- -16.6% 10Y total return vs DYAI's -55.0%
- -62.5% margin vs DYAI's -279.6%
- +17.7% vs DYAI's -32.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.6% revenue growth vs CDXS's 18.6% | |
| Quality / Margins | -62.5% margin vs DYAI's -279.6% | |
| Stability / Safety | Beta 0.98 vs CDXS's 2.31 | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +17.7% vs DYAI's -32.1% | |
| Efficiency (ROA) | -32.6% ROA vs DYAI's -63.0%, ROIC -31.9% vs -16.7% |
DYAI vs CDXS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
DYAI vs CDXS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
CDXS leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CDXS is the larger business by revenue, generating $70M annually — 26.8x DYAI's $3M. Profitability is closely matched — net margins range from -62.5% (CDXS) to -2.8% (DYAI). On growth, CDXS holds the edge at +81.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3M | $70M |
| EBITDAEarnings before interest/tax | -$7M | -$30M |
| Net IncomeAfter-tax profit | -$7M | -$44M |
| Free Cash FlowCash after capex | -$5M | -$24M |
| Gross MarginGross profit ÷ Revenue | +42.2% | +79.5% |
| Operating MarginEBIT ÷ Revenue | -2.7% | -54.5% |
| Net MarginNet income ÷ Revenue | -2.8% | -62.5% |
| FCF MarginFCF ÷ Revenue | -176.1% | -33.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -40.5% | +81.3% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +184.6% |
Valuation Metrics
CDXS leads this category, winning 3 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $28M | $242M |
| Enterprise ValueMkt cap + debt − cash | $26M | $264M |
| Trailing P/EPrice ÷ TTM EPS | -3.80x | -5.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 7.87x | 3.43x |
| Price / BookPrice ÷ Book value/share | 9.02x | 4.59x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CDXS leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
CDXS delivers a -90.5% return on equity — every $100 of shareholder capital generates $-91 in annual profit, vs $-3 for DYAI. CDXS carries lower financial leverage with a 1.45x debt-to-equity ratio, signaling a more conservative balance sheet compared to DYAI's 2.05x. On the Piotroski fundamental quality scale (0–9), CDXS scores 4/9 vs DYAI's 3/9, reflecting mixed financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -2.8% | -90.5% |
| ROA (TTM)Return on assets | -63.0% | -32.6% |
| ROICReturn on invested capital | -16.7% | -31.9% |
| ROCEReturn on capital employed | -87.7% | -30.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 2.05x | 1.45x |
| Net DebtTotal debt minus cash | -$1M | $22M |
| Cash & Equiv.Liquid assets | $7M | $51M |
| Total DebtShort + long-term debt | $5M | $73M |
| Interest CoverageEBIT ÷ Interest expense | -15.72x | -7.96x |
Total Returns (Dividends Reinvested)
CDXS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DYAI five years ago would be worth $1,832 today (with dividends reinvested), compared to $1,342 for CDXS. Over the past 12 months, CDXS leads with a +17.7% total return vs DYAI's -32.1%. The 3-year compound annual growth rate (CAGR) favors CDXS at -7.9% vs DYAI's -24.2% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -19.1% | +65.2% |
| 1-Year ReturnPast 12 months | -32.1% | +17.7% |
| 3-Year ReturnCumulative with dividends | -56.5% | -22.0% |
| 5-Year ReturnCumulative with dividends | -81.7% | -86.6% |
| 10-Year ReturnCumulative with dividends | -55.0% | -16.6% |
| CAGR (3Y)Annualised 3-year return | -24.2% | -7.9% |
Risk & Volatility
Evenly matched — DYAI and CDXS each lead in 1 of 2 comparable metrics.
Risk & Volatility
DYAI is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than CDXS's 2.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDXS currently trades 68.7% from its 52-week high vs DYAI's 56.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 2.31x |
| 52-Week HighHighest price in past year | $1.35 | $3.87 |
| 52-Week LowLowest price in past year | $0.66 | $0.96 |
| % of 52W HighCurrent price vs 52-week peak | +56.3% | +68.7% |
| RSI (14)Momentum oscillator 0–100 | 42.6 | 64.5 |
| Avg Volume (50D)Average daily shares traded | 75K | 2.4M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $5.00 |
| # AnalystsCovering analysts | — | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
CDXS leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
DYAI vs CDXS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is DYAI or CDXS a better buy right now?
For growth investors, Dyadic International, Inc.
(DYAI) is the stronger pick with 20. 6% revenue growth year-over-year, versus 18. 6% for Codexis, Inc. (CDXS). Analysts rate Codexis, Inc. (CDXS) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DYAI or CDXS?
Over the past 5 years, Dyadic International, Inc.
(DYAI) delivered a total return of -81. 7%, compared to -86. 6% for Codexis, Inc. (CDXS). Over 10 years, the gap is even starker: CDXS returned -16. 6% versus DYAI's -55. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DYAI or CDXS?
By beta (market sensitivity over 5 years), Dyadic International, Inc.
(DYAI) is the lower-risk stock at 0. 98β versus Codexis, Inc. 's 2. 31β — meaning CDXS is approximately 135% more volatile than DYAI relative to the S&P 500. On balance sheet safety, Codexis, Inc. (CDXS) carries a lower debt/equity ratio of 145% versus 2% for Dyadic International, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — DYAI or CDXS?
By revenue growth (latest reported year), Dyadic International, Inc.
(DYAI) is pulling ahead at 20. 6% versus 18. 6% for Codexis, Inc. (CDXS). On earnings-per-share growth, the picture is similar: Codexis, Inc. grew EPS 43. 8% year-over-year, compared to 16. 7% for Dyadic International, Inc.. Over a 3-year CAGR, DYAI leads at 13. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DYAI or CDXS?
Codexis, Inc.
(CDXS) is the more profitable company, earning -62. 5% net margin versus -166. 2% for Dyadic International, Inc. — meaning it keeps -62. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDXS leads at -54. 5% versus -168. 8% for DYAI. At the gross margin level — before operating expenses — CDXS leads at 79. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DYAI or CDXS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DYAI or CDXS better for a retirement portfolio?
For long-horizon retirement investors, Dyadic International, Inc.
(DYAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98)). Codexis, Inc. (CDXS) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DYAI: -55. 0%, CDXS: -16. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DYAI and CDXS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.